Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-A*02:01 molecules that enable quick generation of large libraries of peptide-MHC complexes for TCR screening. Read more here.
First publication on the GAPVAC actively personalized vaccine trial conducted by a consortium led by Immatics. The warehouse approach pioneered in GAPVAC was the blueprint for the ongoing ACTolog® clinical trial by Immatics, which applies the multi-target warehouse approach for the first time in ACT. Read more here.
First publication on the proprietary IMADetect® target biomarker screening platform by Immatics as used in all ongoing ACT trials. Immatics uses a unique approach setting the qPCR threshold for each target guided by XPRESIDENT® mass spectrometry. Read more here.
Application of the XPRESIDENT® platform on the therapeutic cancer vaccine IMA901. Development of IMA901 (and of all other cancer vaccines) has been discontinued. However, the paper demonstrates the outstanding capabilities to pioneer biomarker-driven clinical development – as also done in the ongoing Adoptive Cell Therapy (ACT) trials. Read more here.